Carly Helfand

Biography for Carly Helfand

Carly Helfand, News Editor

Carly Helfand is a news editor with Fierce's life sciences group, writing for FiercePharma, FiercePharmaMarketing and FierceVaccines. Carly got her start covering pharma while earning her master’s at Northwestern University’s Medill School of Journalism, where she concentrated in business reporting. She has completed journalism projects on four continents, and her work has appeared in various outlets such as The Boston Globe, The Washington Post’s “Wonkblog” and Cape Town’s Weekend Argus. Carly prefers watching pro hockey to nearly everything. She also plays the Irish fiddle. You can contact her at chelfand@fiercemarkets.com and follow her on Twitter at @CarlyHFierce.

Articles by Carly Helfand

Merck's Zostavax not cost-effective for those in their 50s: Study

The CDC doesn't currently recommend Merck's shingles vaccine, Zostavax, for those between the ages of 50 and 60. And a new analysis of the vaccine's cost-effectiveness in that population suggests it should stay that way.

GSK, U.K. 'hopeful' they can strike a Bexsero price deal soon

It's been 7 months since price negotiations over meningitis B vaccine Bexsero began between Novartis and the U.K. government. And as far as new owner GlaxoSmithKline is concerned, that's long enough.

Cancer vaccine maker Aduro files for $86M IPO

Aduro Biotech is the latest to try its hand at an IPO, and it laid out its case for an $86 million IPO last week.

England to provide GSK MenW vaccine to 3 million teens

England has decided to offer meningitis W vaccination to three million teens after a steep rise in cases--and local vaccine giant GlaxoSmithKline will be reaping the benefits.

More vaccines deals for Pfizer? It wouldn't say no, exec says

Over the past year, Pfizer has certainly achieved CEO Ian Read's goal of bulking up beyond best-selling vaccine Prevnar 13. In addition to ushering its meningitis B vaccine through the clinic to an FDA approval, it's made two pickups to expand its marketed portfolio and pipeline. So what's next for the pharma giant's vaccines unit? Perhaps more deals, its leader says.

Combo-happy Diamyd launches new diabetes vaccine trial in children

Diabetes vaccine developer Diamyd Medical is running a Phase II test to see if its candidate, Diamyd, can prevent or delay the onset of Type 1 diabetes in children at very high risk of presenting with the disease.

Analyst: Ebola vaccine developers 'need to weigh risks' as cases dwindle

The number of Ebola cases in West Africa has been declining, which has made it more difficult to enroll patients for clinical trials of leading vaccine candidates. And the way GlobalData analyst Daian Cheng sees it, that means it's time for vaccine manufacturers to "weigh the risks and benefits of developing further interventions for a disease that goes through unpredictable cycles of intense outbreaks followed by its virtual disappearance."

Takeda transfers HPV vaccine rights as it continues globalization push

Takeda has been singing a globalization mantra when it comes to its vaccines unit, and that's already led it to dump one R&D program as it zeroes in on "higher impact" public health endeavors. Now, it's bowing out of another vaccine program--this time for HPV.

Bharat's $1 rotavirus vaccine rolls out in India to challenge GSK, Merck

Back in 2011, Indian company Bharat Biotech pledged to offer its rotavirus prospect at a price that undercut even discounted vaccines from GlaxoSmithKline and Merck. Now, it's ready to make good on its promise.

Bristol-Myers bets $1B on Bavarian Nordic cancer vaccine

After a handful of large-scale monotherapy flops for cancer vaccines, many companies now think pairing them up as part of immunotherapy combos might be the way to go. And immuno-oncology pioneer Bristol-Myers Squibb just made a big bet that that's the case.